Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma

We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Attia, Steven, Okuno, Scott H., Robinson, Steven I., Webber, Nicholas P., Indelicato, Daniel J., Jones, Robin L., Bagaria, Sanjay P., Sherman, Courtney, Kozak, Kevin R., Cortese, Cherise M., McFarland, Thomas, Trent, Jonathan C., Maki, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508650/
https://www.ncbi.nlm.nih.gov/pubmed/26266019
http://dx.doi.org/10.4081/rt.2015.5992
Descripción
Sumario:We report a response to pazopanib in a 69-year-old man with heavily pre-treated metastatic extraosseous Ewing sarcoma in addition to molecular profiling of his tumor. To our knowledge, this case is the earliest to demonstrate activity of an oral multi-targeted kinase inhibitor in Ewing sarcoma. This case provides rationale for adding a Ewing sarcoma arm to SARC024, a phase II study of regorafenib, another multi-targeted kinase inhibitor, in patients with liposarcoma, osteosarcoma and Ewing and Ewing-like sarcomas (NCT02048371). This national multi-institutional study is ongoing.

Ejemplares similares